ReviewNature reviews. Endocrinology2023
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases.
Review in Nature reviews. Endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Short-term effects of high-protein, lower-carbohydrate ultra-processed foods on human energy balance.Nature metabolism · 2025Trial
- Effect of Isocaloric Meals on Postprandial Glycemic and Metabolic Markers in Type 1 Diabetes-A Randomized Crossover Trial.Nutrients · 2023Trial
- Computational discovery of fenugreek-paitan-turmeric (FPT) bioactive compounds targeting SGLT2 and DPP-4 for glucose homeostasis regulation.Journal of Taibah University Medical Sciences · 2026Article
- Defining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity.Journal of cachexia, sarcopenia and muscle · 2026Review
- Loss of Slc39a5 in α-cells impairs glucose metabolism by chronically increasing glucagon.Journal of advanced research · 2026Article
- Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Article
- Chronic Glycaemic Control Modulates the Relationship Between GIP and Glucagon Secretion Following Oral and Enteral Nutrients in Type 2 Diabetes.Diabetes, obesity & metabolism · 2026Article
- Distinct metabolic signatures of Alzheimer's and Parkinson's disease revealed through genetic overlap.EBioMedicine · 2026Article
- CBP/p300 is critical for the expansion and maintenance of functional pancreatic α cell mass.Nature communications · 2026Article
- Management of Obese Patients with Cardiovascular Disease with Emerging Weight-Lowering Drugs: A Narrative Review.Biomedicines · 2026Review
- Impact of obesity on aromatic amino acids and brain glucose during acute hyperglycemia.American journal of physiology. Endocrinology and metabolism · 2026Article
- Development of a severe rat refeeding syndrome model and mathematical modeling of the associated hypophosphatemia.NPJ systems biology and applications · 2026Article
- Identification of modifiable plasma protein markers of cardiometabolic risk in children and adolescents with obesity.Nature communications · 2026Article
- Prolonged Somatostatin Receptor 2 Antagonism Enhances Glucagon Response to Hypoglycemia in Male Diabetic Rats.Endocrinology · 2026Article
- Mosloflavone induces pancreatic α cells transdifferentiation into β cells through PDX1.Journal of natural medicines · 2026Article
- Cold exposure and human metabolism: A heterogeneous response across tissues and organs.Temperature (Austin, Tex.) · 2026Review
- Differential association of hyperglucagonemia with C-peptide levels in diabetic ketosis/ketoacidosis and hyperosmolar hyperglycemic state.Diabetology international · 2026Article
- Genome-wide CRISPR Screen Identifies Sec31A as a Key Regulator of Alpha Cell Survival.Nature communications · 2025Article
- Glucagon in Pediatric Metabolic Disorders: Pathophysiology and Therapeutic Perspectives.Pediatric reports · 2025Review
- Dynamic multi-omics profiling of islet and gut hormonal secretion and peripheral crosstalk in response to various nutrient loads.Cell reports. Medicine · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin and glucagon exert opposing effects on glucose metabolism and, consequently, pancreatic islet β-cells and α-cells are considered functional antagonists. The intra-islet hypothesis has previously dominated the understanding of glucagon secretion, stating that insulin acts to inhibit the release of glucagon. By contrast, glucagon is a potent stimulator of insulin secretion and has been used to test β-cell function. Over the past decade, α-cells have received increasing attention due to their ability to stimulate insulin secretion from neighbouring β-cells, and α-cell-β-cell crosstalk has proven central for glucose homeostasis in vivo. Glucagon is not only the counter-regulatory hormone to insulin in glucose metabolism but also glucagon secretion is more susceptible to changes in the plasma concentration of certain amino acids than to changes in plasma concentrations of glucose. Thus, the actions of glucagon also include a central role in amino acid turnover and hepatic fat oxidation. This Review provides insights into glucagon secretion, with a focus on the local paracrine actions on glucagon and the importance of α-cell-β-cell crosstalk. We focus on dysregulated glucagon secretion in obesity, non-alcoholic fatty liver disease and type 2 diabetes mellitus. Lastly, the future potential of targeting hyperglucagonaemia and applying dual and triple receptor agonists with glucagon receptor-activating properties in combination with incretin hormone receptor agonism is discussed.
Indexed as
Identifiers
36932176What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.